Weiss Ratings Reaffirms Sell (E+) Rating for 180 Life Sciences (NASDAQ:ATNF)

180 Life Sciences (NASDAQ:ATNF)‘s stock had its “sell (e+)” rating reiterated by equities researchers at Weiss Ratings in a report released on Saturday,Weiss Ratings reports.

180 Life Sciences Stock Performance

Shares of ATNF stock traded down $0.02 during trading on Friday, reaching $1.56. 85,595 shares of the company’s stock traded hands, compared to its average volume of 1,006,117. 180 Life Sciences has a 1 year low of $1.16 and a 1 year high of $17.75. The firm’s 50-day moving average is $2.10 and its 200 day moving average is $2.24.

About 180 Life Sciences

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor.